Business Wire

TINUBU-SQUARE

15.12.2020 15:02:15 CET | Business Wire | Press release

Share
Tinubu® Square’s Acquisition of SuretyWave Streamlines Agent-Carrier Surety Tech Connection

Tinubu® Square Group, the global technology leader in the surety and credit insurance industry, announced today it has acquired the assets of SuretyWave LLC, including its technology and knowledge base, notably the cloud-based surety bond processing system known as SurePath Digital.

The acquisition continues Tinubu Square’s execution of its global strategic vision of building highly complementary and integrated enterprise software solutions and services for credit and surety insurers. This enables clients, brokers, agents, obligees, and carriers to manage their rapidly evolving, high-growth businesses efficiently.

With the acquisition, Tinubu Square’s end-to-end SaaS platform simplifies processing for an entire value chain that has long struggled with disparate, complex surety bond information. Agents, brokers and carrier partners can now efficiently manage their bond requirements, premiums, commission and other calculations.

Tinubu Square is the global leader in designing, producing and servicing the largest providers of financial guarantee products. The Paris-based firm provides technology solutions to 30 of the top 60 credit and surety underwriters in the United States and globally.

Jérôme Pezé, co-founder and CEO, says, “We are now even closer to a global promise of full automation and digitalization of surety and credit insurance products.”

SurePath Digital “is an outstanding insurtech solution because of its proven ability to streamline connections for independent agencies and brokers, which are key business partners to carriers that stand behind bonds,” Pezé adds. “These bond producers add significant value for customers, but desperately need the appropriate technology solution for their business to reduce manual processing, be more efficient for their customers, and grow profitably.”

Earlier this year, Tinubu Square acquired another U.S.-based insurtech, eSURETY®, which provides cloud-based solutions for automated underwriting, account risk analysis, bond lifecycle management and surety analytics at an enterprise level.

“The Tinubu eSURETY solution, its team’s expertise, and its brand recognition brought highly complementary capabilities to our combined existing and future customers,” says Pezé. “What that platform provides for surety carriers, SurePath Digital does for agents and brokers. SurePath significantly reduces the cost of executing and managing surety bonds through automation of administration, processing and reporting functions.

“These capabilities have strengthened our position in the global surety marketplace, providing an end-to-end cloud-based platform,” Pezé adds.

Daniel T. Buckles, deputy CEO and president, surety, of Tinubu Square Americas, notes that the surety bond business “is highly complex but too often still paper-based for multiline agents and brokers and their carrier partners. SurePath Digital is the key to continue to make it less cumbersome so our partners can focus on completing deals. We are building technology bridges in the surety industry where there have been none.”

“We are excited for SurePath Digital to be aligned with an industry leader in Tinubu Square,” says W. Patrick McGinty CPCU, president of SuretyWave. “Existing clients of Tinubu eSURETY and SuretyWave continue to be in safe hands, as the companies concentrate on sustainability and continuity for their software users. Tinubu Square has the same determined focus, innovative technology, and customer-centricity that provide a best-in-class customer experience and product.”

Olivier Placca, Tinubu Square co-founder and group deputy CEO, states, “By investing 20% of revenue in research and development on a yearly basis, Tinubu Square will support further innovation for the benefit of SurePath Digital’s clients. It reinforces our commitment to making this a long-term partnership.”

Placca adds: “Our solution can grow and make an even more significant positive impact in the surety business. Tinubu Square’s enterprise solutions lead the way in supporting an open ecosystem for all players in the surety and credit insurance industry. We are reducing the duplication of tasks, including the many manual tasks still in use. This reduces administrative costs, improves processes and operations, and eases the two-way communication between brokers and agents with underwriters.”

About SuretyWave
In 2017, Steckler Group acquired Insure Vision Technologies (IVT) and renamed the company as SuretyWave. IVT, founded in 1999, was formed to develop a cloud-based surety bond processing system that significantly reduces the cost of executing and managing surety bonds. IVT founders Pam Stocks and Bev Hall helped lead surety industry efforts by being active with ACORD’s standard setting committee for electronic interface between carriers and brokers/agents and with the National Association of Surety Bond Producers (NASBP) Surety Automation Committee and Commercial Surety Committee.

About Tinubu Square
Tinubu® Square is the industry-leading insurtech SaaS (software as a service) platform vendor, enabling credit insurance and surety digital transformation. With 170+ employees globally and 20 years of innovation, Tinubu Square empowers its customers to offer best-in-class client experience; reduce exposure to risk; and lower financial, operational and technology costs. The firm has a footprint with customers in over 20 countries, including 30 of the top 60 worldwide credit and surety underwriters and invests 20% of its annual revenue in research and development. Visit www.tinubu.com/ for more information.

Link:

ClickThru

Social Media:

https://www.facebook.com/tinubu.square.35

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye